Published in Neuroscience on May 11, 2013
The Physiology of Bone Pain. How Much Do We Really Know? Front Physiol (2016) 0.78
Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. Pain (2017) 0.75
Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol (2017) 0.75
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Cellular and molecular mechanisms of pain. Cell (2009) 9.36
Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol (2007) 6.35
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
The cannabinoid system and immune modulation. J Leukoc Biol (2003) 2.87
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain (2001) 2.59
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 2.43
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 1.76
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience (1999) 1.73
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest (2003) 1.61
Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. Eur J Pain (2012) 1.61
Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage (2000) 1.59
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience (2000) 1.56
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther (2000) 1.52
Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci (2001) 1.50
The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther (1975) 1.49
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol (2001) 1.49
A unifying purinergic hypothesis for the initiation of pain. Lancet (1996) 1.45
Roles of transient receptor potential channels in pain. Brain Res Rev (2008) 1.44
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain (2007) 1.43
Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol (1975) 1.42
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A (2006) 1.39
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett (1997) 1.39
Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain (1999) 1.36
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci (2008) 1.31
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids (2002) 1.29
Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience (2003) 1.27
Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol (1998) 1.27
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain (2003) 1.25
The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience (2003) 1.20
The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol (2006) 1.16
Cannabinoid analgesia. Pharmacol Ther (2002) 1.15
Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain (2005) 1.14
A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci (2008) 1.13
The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci (1999) 1.12
Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain (2001) 1.12
Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci (2007) 1.06
Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol (2006) 1.06
Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci (2004) 1.06
Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain (2010) 1.06
Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther (1977) 1.02
Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 1.01
Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Res (2005) 1.00
Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage (2001) 1.00
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. Neuroscience (2002) 0.98
Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol (2008) 0.98
Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res (2011) 0.97
Cultured human keratinocytes synthesize and secrete endothelin-1. J Invest Dermatol (1993) 0.97
Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett (2008) 0.96
Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage (2005) 0.95
Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience (2002) 0.95
Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med (2001) 0.93
Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain (2003) 0.93
Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res (2005) 0.92
The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res (2008) 0.92
Tumor-evoked sensitization of C nociceptors: a role for endothelin. J Neurophysiol (2008) 0.90
The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain (1999) 0.90
Topical cannabinoid enhances topical morphine antinociception. Pain (2003) 0.89
Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett (2010) 0.88
Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl) (1999) 0.87
Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience (2009) 0.86
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav (2008) 0.84
Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage (2010) 0.83
The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. Acta Physiol Hung (2010) 0.83
The role of purinergic receptors in cancer-induced bone pain. J Osteoporos (2012) 0.83
CB1 cannabinoid receptors in amphibian spinal cord: relationships with some nociception markers. J Chem Neuroanat (2002) 0.82
The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. Pflugers Arch (2006) 0.78
Human tumor tissues have higher ATP contents than normal tissues. Clin Chim Acta (1987) 0.77
Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol (1980) 0.76
Cannabinoids inhibit ATP-activated currents in rat trigeminal ganglionic neurons. Sheng Li Xue Bao (2007) 0.76
Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients. Compr Psychiatry (1976) 0.75
Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 4.03
Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol (1991) 2.54
Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science (1999) 2.43
Neurogenic hyperalgesia: the search for the primary cutaneous afferent fibers that contribute to capsaicin-induced pain and hyperalgesia. J Neurophysiol (1991) 2.33
Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain (1999) 1.90
Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study. J Neurophysiol (2001) 1.62
A new device to quantify tactile sensation in neuropathy. Neurology (2011) 1.62
Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. Pain (1996) 1.49
Windup leads to characteristics of central sensitization. Pain (1999) 1.29
Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. Pain (1997) 1.27
Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci (2001) 1.24
Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci (1997) 1.18
Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain (2001) 1.12
Pain from excitation of identified muscle nociceptors in humans. Brain Res (1996) 1.12
Peripheral and preemptive opioid antinociception in a mouse visceral pain model. Pain (2001) 1.07
Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci (2004) 1.06
Single C nociceptor responses and psychophysical parameters of evoked pain: effect of rate of rise of heat stimuli in humans. J Physiol (1992) 1.04
The role of pH and osmolarity in evoking the acetic acid-induced wiping response in a model of nociception in frogs. Brain Res (2000) 0.99
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. Neuroscience (2002) 0.98
Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience (2005) 0.96
Primary afferent fibers that contribute to increased substance P receptor internalization in the spinal cord after injury. J Neurophysiol (1999) 0.94
Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med (2001) 0.93
The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain (1999) 0.90
Influence of thermode size for detecting heat pain dysfunction in a capsaicin model of epidermal nerve fiber loss. Pain (2001) 0.89
Capsaicin-evoked CGRP release from rat buccal mucosa: development of a model system for studying trigeminal mechanisms of neurogenic inflammation. Eur J Neurosci (2001) 0.87
Involvement of opioid receptor subtypes in rat feeding behavior. Life Sci (1985) 0.86
Developmental shift of vanilloid receptor 1 (VR1) terminals into deeper regions of the superficial dorsal horn: correlation with a shift from TrkA to Ret expression by dorsal root ganglion neurons. Eur J Neurosci (2001) 0.84
Enhanced responses of spinal dorsal horn neurons to heat and cold stimuli following mild freeze injury to the skin. J Neurophysiol (2001) 0.83
Loss of neurons in rostral ventromedial medulla that express neurokinin-1 receptors decreases the development of hyperalgesia. Neuroscience (2013) 0.82
P2X receptors in sensory neurons co-cultured with cancer cells exhibit a decrease in opioid sensitivity. Eur J Neurosci (2008) 0.81
Anesthetic blockade of the dorsolateral funiculus enhances evoked activity of spinal cord dorsal horn neurons. J Neurophysiol (1991) 0.80
Animal models of cancer pain may reveal novel approaches to palliative care. Pain (2001) 0.80
Changes in response properties of rostral ventromedial medulla neurons during prolonged inflammation: modulation by neurokinin-1 receptors. Neuroscience (2012) 0.78
Capsaicin treatment and stress-induced analgesia. Pharmacol Biochem Behav (1983) 0.75
Is the decision to merge really a question of access to capital? Trustee (1982) 0.75
Antagonism of morphine analgesia by intracerebroventricular naloxonazine. Pharmacol Biochem Behav (1986) 0.75
Bond markets restrict borrowing; may force new financing strategies. Mod Healthc (1980) 0.75
Dissociation of analgesic and hyperphagic responses following 2-deoxy-D-glucose. Int J Neurosci (1983) 0.75
Strategic financial planning: opportunities at an inopportune time? Trustee (1984) 0.75
Modulation of antinociceptive responses following tail pinch stress. Life Sci (1982) 0.75